Alteogen Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 131

Employees

  • Stock Symbol
  • 196170

Stock Symbol

  • Share Price
  • $198.43
  • (As of Friday Closing)

Alteogen General Information

Description

Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 62, Yuseong-daero 1628beon-gil
  • Yuseong-gu
  • Daejeon, 34054
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alteogen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$198.43 $194.59 $31.56 - $214.00 $10.5B 53M 1.34M $0.37

Alteogen Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 7,656,380 3,878,006 1,448,463 2,521,596
Revenue 91,673 73,825 22,294 33,827
EBITDA 18,724 (3,634) (8,327) (8,734)
Net Income 19,337 (2,579) (6,304) (5,478)
Total Assets 203,242 198,731 194,384 217,071
Total Debt 1,198 1,323 3,426 3,161
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alteogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alteogen‘s full profile, request access.

Request a free trial

Alteogen Patents

Alteogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3240340-A1 N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof Pending 22-Jun-2022 0000000000
AU-2023289270-A1 N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof Pending 22-Jun-2022 0000000000
CA-3236277-A1 Pharmaceutical composition comprising human hyaluronidase ph20 and drug Pending 29-Oct-2021 0000000000
AU-2022376750-A1 Pharmaceutical composition comprising human hyaluronidase ph20 and drug Pending 29-Oct-2021 0000000000
AU-2022369694-A1 Method for purifying fusion protein having igg fc domain Pending 19-Oct-2021 C07K14/71
To view Alteogen’s complete patent history, request access »

Alteogen Executive Team (9)

Name Title Board Seat Contact Info
Soonjae Park Chief Executive Officer
HangYeon Kim Chief Financial Officer & Executive Vice President
Hye-Shin Chung Ph.D Founder & Chief Technology Officer
Tae Yon Chun Ph.D Corporate Alliance Officer & Executive Vice President
Vivek Shenoy Ph.D Chief Business Development Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Alteogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alteogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alteogen‘s full profile, request access.

Request a free trial

Alteogen ESG

Risk Overview

Risk Rating

Updated July, 28, 2023

29.39 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Alteogen’s complete esg history, request access »

Alteogen FAQs

  • When was Alteogen founded?

    Alteogen was founded in 2008.

  • Who is the founder of Alteogen?

    Hye-Shin Chung Ph.D is the founder of Alteogen.

  • Who is the CEO of Alteogen?

    Soonjae Park is the CEO of Alteogen.

  • Where is Alteogen headquartered?

    Alteogen is headquartered in Daejeon, South Korea.

  • What is the size of Alteogen?

    Alteogen has 131 total employees.

  • What industry is Alteogen in?

    Alteogen’s primary industry is Drug Discovery.

  • Is Alteogen a private or public company?

    Alteogen is a Public company.

  • What is Alteogen’s stock symbol?

    The ticker symbol for Alteogen is 196170.

  • What is the current stock price of Alteogen?

    As of 12-Jul-2024 the stock price of Alteogen is $198.43.

  • What is the current market cap of Alteogen?

    The current market capitalization of Alteogen is $10.5B.

  • What is Alteogen’s current revenue?

    The trailing twelve month revenue for Alteogen is $91.7M.

  • What is Alteogen’s annual earnings per share (EPS)?

    Alteogen’s EPS for 12 months was $0.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »